Table 1.
Important features of included studies
| Author | Country | Mean age ± SD | Sex (male %) | Type of study | No. of patients | Study groups | Treatment onset from symptom onset | Stage of disease | |
|---|---|---|---|---|---|---|---|---|---|
| Intervention | control | ||||||||
| Bo Wang 12 | China | 56.2 ± 9.7 | 44% | Single‐center, retrospective cohort study | 41 | LPV/r 200 mg/50 mg/pill), 400 mg/time, twice a day in combination with IFN α ‐2b | LPV/r | Intervention: 12 ± 7.3 Control: 11 ± 6.8 | Hospitalized |
| Yin‐Qiu Huang 10 | China | 42.5 | 46% | RCT | 101 | (A) RBV and IFN‐α, (B) LPV/r and IFN‐α, (C) RBV and LPV/r and IFN‐α at a 1:1:1 ratio | Not defined | Mild to moderate | |
| Qiong Zhou 7 | China | 41.3 | IFN: 0.0% IFN + ARB:4 3.5% ARB: 45.8% | Cohort uncontrolled, exploratory study | Total :77 IFN‐α2b: 7ARB: 24 IFN‐α2b + ARB: 46 | IFN‐ α2b (5 mU b.i.d) 1 ml in 2 ml of sterile water | ARB (200 mg t.i.d.) or IFN‐α2b and ARB | IFN:8 (5.5, 15.5) IFN + ARB: 6.5 (3, 10) ARB: 10 (4.5, 19.9) | Moderate |
| Yan Zuo 8 | China | 44.3 ± 13.3 | 55.2% | Retrospective study | 181 | LPV/r and IFN‐α | Not defined | <5 days from onset versus ≥5 days | Severe (34%) versus non severe |
| Ping Xu 13 | China | 52.4 | 60% | Retrospective multicenter cohort | 141 | IFN‐α2b | ARB (200 mg, oral, three times per day, for 7–10 days)/with IFN‐α2b combination | Not defined | Not defined |
Abbreviations: ARB, Arbido; INF, interferon; LPV/r, lopinavir/ritonavir; RBV, ribavirin; RCT, randomized controlled trial.